MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2007.04.050

Медицинская библиотека · Vaccine · 2007

Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults.

Kshirsagar Nilima, Mur Naidu, Thatte Urmila, Gogtay Nithya, Viviani Simonetta, Préziosi Marie-Pierre, Elie Cheryl, Findlow Helen, Carlone George, Borrow Ray, Parulekar Varsha, Plikaytis Brian, Kulkarni Prasad, Imbault Nathalie, LaForce F Marc

Клиническое исследование I фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

We performed a double-blind, randomized, controlled phase I study to assess safety, immunogenicity, and antibody persistence of the new meningococcal group A conjugate vaccine (PsA-TT) in healthy volunteers aged 18-35 years. Of the 74 male subjects enrolled, 24 received the PsA-TT vaccine (Group 1), 25 received the Meningococcal Polysaccharide Vaccine A+C, Pasteur, Lyon, France (Group 2), and 25 received the Tetanus Toxoid Vaccine Adsorbed, SIIL, Pune India (Group 3). No immediate reactions were observed. Local and systemic solicited reactions within 7 days post-vaccination and unsolicited adverse events (AEs) were mild and similar among the three groups and resolved without sequelae. No serious AEs were notified up to 1 year post-vaccination. Four weeks post-vaccination, a slightly higher proportion of Group 1 subjects had a four-fold increase in SBA titers compared to Group 2 subjects (83% versus 72%, p>0.05). SBA GMTs in Groups 2 and 3 were higher than in Group 3 (p<0.05). Serogroup A-specific IgG GMCs were significantly higher in Group 1 than in Groups 2 (p<0.05) and 3 (p<0.05). After 1 year SBA titers were significantly higher in Group 1 than in Group 2 (p<0.05). The new PsA-TT vaccine was shown to be safe, immunogenic, and able to elicit persistent functional antibody titers in adults. This opens the prospective for further development and licensure of this vaccine to eliminate epidemic meningitis in sub-Saharan Africa.

Для цитирования: Kshirsagar Nilima, Mur Naidu, Thatte Urmila, Gogtay Nithya, Viviani Simonetta, Préziosi Marie-Pierre, Elie Cheryl, Findlow Helen, Carlone George, Borrow Ray, Parulekar Varsha, Plikaytis Brian, Kulkarni Prasad, Imbault Nathalie, LaForce F Marc. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults.. Vaccine. 2007. DOI: 10.1016/j.vaccine.2007.04.050.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.